Comparative Pharmacology
Head-to-head clinical analysis: BUSPAR versus TRANMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPAR versus TRANMEP.
BUSPAR vs TRANMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, leading to reduced serotonergic activity; also has antagonist activity at D2 and 5-HT2 receptors.
Tianeptine is a selective serotonin reuptake enhancer (SSRE) and also modulates glutamatergic signaling via AMPA and NMDA receptors. It increases serotonin transport in presynaptic neurons and enhances neuroplasticity.
Initial: 7.5 mg orally twice daily; may increase by 5 mg/day every 2-3 days. Usual: 20-30 mg/day in divided doses; max 60 mg/day.
50 mg orally every 8 hours, may increase to 100 mg every 8 hours if needed.
None Documented
None Documented
2–3 hours (terminal); clinical context: requires multiple daily dosing; steady-state achieved in ~2 days
4-6 hours in adults; prolonged in hepatic impairment (up to 12 hours) and elderly.
Renal: 29–63% (primarily as metabolites, <1% unchanged); Fecal: 34–38%; Biliary: minimal
Renal: ~60% as unchanged drug, biliary/fecal: ~30% as metabolites, remainder as unchanged drug.
Category C
Category C
Anxiolytic
Anxiolytic